Refractory Multiple Myeloma (Oncology) - Drugs in Development, 2021
Summary Refractory Multiple Myeloma (Oncology) - Drugs in Development, 2021 provides an overview of the Refractory Multiple Myeloma pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Refractory Multiple Myeloma, complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive Pharmacological Action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Refractory Multiple Myeloma and features dormant and discontinued projects.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: * This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase. * Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope - The report provides a snapshot of the Global Therapeutic Landscape of Refractory Multiple Myeloma (Oncology). - The report reviews pipeline therapeutics for Refractory Multiple Myeloma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The report covers pipeline products based on various stages of development ranging from discovery till pre-registration. - The report features descriptive drug profiles for the pipeline products which includes, Product Description, Descriptive MoA, R&D Brief, Licensing and Collaboration details & Other Developmental Activities. - The report reviews key players involved in the development of Refractory Multiple Myeloma (Oncology) therapeutics and enlists all their major and minor projects. - The report assesses Refractory Multiple Myeloma (Oncology) therapeutics based on Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. - The report summarizes all the dormant and discontinued pipeline projects. - The report reviews latest news related to pipeline therapeutics for Refractory Multiple Myeloma (Oncology).
Reasons to Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective Research and Development (R&D) strategies. - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Identify and understand important and diverse types of therapeutics under development for Refractory Multiple Myeloma (Oncology). - Identify potential new clients or partners in the target demographic. - Develop strategic initiatives by understanding the focus areas of leading companies. - Plan Mergers and Acquisitions (M&A) effectively by identifying key players and it’s most promising pipeline therapeutics. - Devise corrective measures for pipeline projects by understanding Refractory Multiple Myeloma (Oncology) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Our reports have been used by over 10K customers, including:
Rectal Cancer (Oncology) - Drugs In Development, 2021 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Rectal Cancer - Drugs In Development, 2021, provides an overview of the Rectal Cancer (Oncology) pipeline landscape. Rectal cancer affects the lower part of the colon,...
“Osteosarcoma - Pipeline Insight, 2021,” report provides comprehensive insights about 38+ companies and 38+ pipeline drugs in Osteosarcoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and...
‘HPV 16+ Cancer– Market Insights, Epidemiology, and Market Forecast—2030’ report deliver an in-depth understanding of the HPV 16+ Cancer, historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. The HPV 16+ Cancer market report provides...
Global Flow Cytometry in Oncology Market to Reach $5.25 Billion by 2031 Market Report Coverage - Flow Cytometry in Oncology Market Segmentation • Product Type – Assays and Kits, Instruments, Reagents and Consumables, and Software • Technology – Cell-Based and Bead-Based • Type of...
The Global Oncology Partnering 2015-2021: Deal trends, players and financials report provides an understanding and access to the oncology partnering deals and agreements entered into by the worlds leading healthcare companies. Trends in Oncology partnering deals Financial deal terms for headline, upfront and royalty...
The global nuclear medicine market is projected to reach USD 7.5 billion by 2026 from USD 4.8billion in 2021, at a CAGR of 9.0% during the forecast period. Growth in the nuclear medicine market can primarily be attributed to factors such as the increasing incidence and prevalence of cancer and cardiac ailments and initiatives to lessen the...
Ewing Sarcoma - Global Clinical Trials Review, H2, 2021
clinical trial report, “Ewing Sarcoma - Global Clinical Trials Review, H2, 2021" provides an overview of Ewing Sarcoma Clinical trials scenario. This report provides top line data relating to the clinical trials on Ewing Sarcoma....
Global Bone Void Fillers Market, By Material (Demineralized Bone Matrix (DBM), Calcium Sulphate, Tri-Calcium Phosphate, Others), By Form (Gel, Granules, Paste, Others), By Procedure (Spine Fusion, Interbody Fusion, Oral Surgeries, Others), By End User (Hospitals, Specialty Clinics, Others), By Company, By Region, Forecast & Opportunities,...
Germ Cell Tumors - Global Clinical Trials Review, H2, 2021
clinical trial report, “Germ Cell Tumors - Global Clinical Trials Review, H2, 2021" provides an overview of Germ Cell Tumors Clinical trials scenario. This report provides top line data relating to the clinical trials on Germ Cell...
Head and Neck Squamous Cell Carcinoma - Epidemiology Forecast to 2030
Head and neck cancers (HNCs) are a heterogeneous group consisting of cancers of the mouth, including the lip, tongue, gum, floor of mouth, palate, and other parts of mouth (ICD-10 code = C00-C06),; the salivary glands...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.